Background: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a key player in the extrinsic pathway of apoptosis; it selectively damages cancer cells through binding to its surface receptors, however, cancers can escape this pathway through expression of dysfunctional decoy receptors. Purpose: The present study directed mainly to elucidate the serum TRAIL levels in breast cancer patients and to explore the variation in gene expression of TRAIL death and decoy receptors in breast cancer tissues, and to explore their role as prognostic markers in breast cancer as well as to detect their correlation with Patients’ Clinical Characteristics. Subjects and Methods: TRAIL levels were assayed in the sera of 124 breast cancer patients and 150 healthy females. Moreover, the expression of TRAIL death and decoy receptors was determined in both malignant and adjacent normal breast tissues collected from patients. ER, PR and Her-2 expression in breast cancer tissue were performed using immunohistochemical method. Apoptotic index (AI) was analyzed using H&E stain under light microscopy. Results: Serum levels of TRAIL in breast cancer patients were significantly lower than controls (P < 0.001), additionally, the expression of DR4, DR5 and DcR1 were significantly up-regulated (p < 0.001, p < 0.001, p = 0.039, respectively), however, no significant difference was found in the expression of DcR2 in breast cancer tissues as compared to the corresponding normal tissues. Moreover, the apoptotic index in breast cancer tissues was significantly higher than the corresponding normal tissues. On the other side, decreased Serum TRAIL levels and increased DcR1 expression were associated with decreased overall patients’ survival. Conclusions: The expression of both DR4 and DR5 is required for TRAIL-induced apoptosis in breast cancer tissues; in addition, serum TRAIL and profiling of TRAIL receptors expression may serve as prognostic markers in breast cancer patients.
KeywordsBreast CancerApoptosisTRAILPrognosis
Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674. https://doi.org/10.1016/j.cell.2011.02.013
Herrnring, C., Reimer, T., Jeschke, U., Makovitzky, J., Kruger, K., et al. (2000) Expression of the Apoptosis-Inducing Ligands FasL and TRAIL in Malignant and Benign Human Breast Tumors. Histochemistry and Cell Biology, 113, 189-194. https://doi.org/10.1007/s004180050438
Rahman, M., Pumphrey, J.G. and Lipkowitz, S. (2009) The TRAIL to Targeted Therapy of Breast Cancer. Advances in Cancer Research, 103, 43-73. https://doi.org/10.1016/S0065-230X(09)03003-6
Sheridan, J.P., Marsters, S.A., Pitti, R.M., Gurney, A., Skubatch, M., Baldwin, D., et al. (1997) Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors. Science, 277, 818-821. https://doi.org/10.1126/science.277.5327.818
MacFarlane, M. (2003) TRAIL-Induced Signalling and Apoptosis. Toxicology Letters, 139, 89-97. https://doi.org/10.1016/S0378-4274(02)00422-8
Lemke, J., von Karstedt, S., Zinngrebe, J. and Walczak, H. (2014) Getting TRAIL Back on Track for Cancer Therapy. Cell Death & Differentiation, 21, 1350-1364. https://doi.org/10.1038/cdd.2014.81
Cretney, E., Takeda, K., Yagita, H., Glaccum, M., Peschon, J.J., et al. (2002) Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosisinducing Ligand-Deficient Mice. The Journal of Immunology, 168, 1356-1361. https://doi.org/10.4049/jimmunol.168.3.1356
Kriegl, L., Jung, A., Engel, J., Jackstadt, R., Gerbes, A.L., et al. (2010) Expression, Cellular Distribution, and Prognostic Relevance of TRAIL Receptors in Hepatocellular Carcinoma. Clinical Cancer Research, 16, 5529-5538. https://doi.org/10.1158/1078-0432.CCR-09-3403
De Toni, E.N., Thieme, S.E., Herbst, A., Behrens, A., Stieber, P., et al. (2008) OPG Is Regulated by Beta-Catenin and Mediates Resistance to TRAIL-Induced Apoptosis in Colon Cancer. Clinical Cancer Research, 14, 4713-4718. https://doi.org/10.1158/1078-0432.CCR-07-5019
Allred, D.C., Harvey, J.M. and Berardo, M. (1998) Prognostic and Predictive Factors in Breast Cancer by Immunohistochemical Analysis. Modern Pathology, 11, 155-168.
Wolff, A.C., Hammond, M.E. and Schwartz, J.N. (2007) American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Journal of Clinical Oncology, 25, 118-145. https://doi.org/10.1200/JCO.2006.09.2775
Shlyakhtina, Y., Pavet, V. and Gronemeyer, H. (2017) Dual Role of DR5 in Death and Survival Signaling Leads to TRAIL Resistance in Cancer Cells. Cell Death & Disease, 8, e3025. https://doi.org/10.1038/cddis.2017.423
Koschny, R., Ganten, T.M., Sykora, J., Haas, T.L., Sprick, M.R., et al. (2007) TRAIL/Bortezomib Cotreatment Is Potentially Hepatotoxic Butinduces Cancer-Specific Apoptosis within a Therapeutic Window. Journal of Hepatology, 45, 649-658. https://doi.org/10.1002/hep.21555
Toiyama, D., Takaha, N., Shinnoh, M., Ueda, T., Kimura, Y., et al. (2013) Significance of Serum Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand as a Prognostic Biomarker for Renal Cell Carcinoma. Molecular and Clinical Oncology, 1, 69-74. https://doi.org/10.3892/mco.2012.35
Tecchio, C., Huber, V., Scapini, P., et al. (2004) IFNalpha-Stimulated Neutrophils and Monocytes Release a Soluble Form of TNF-Related Apoptosis-Inducing Ligand (TRAIL/Apo-2 Ligand) Displaying Apoptotic Activity on Leukemic Cells. Blood, 103, 3837-3844. https://doi.org/10.1182/blood-2003-08-2806
Tanaka, H., Ito, T., Kyo, T. and Kimura, A. (2007) Treatment with IFNalpha in Vivo Up-Regulates Serum-Soluble TNF-Related Apoptosis Inducing Ligand (sTRAIL) Levels and TRAIL mRNA Expressions in Neutrophils in Chronic Myelogenous Leukemia Patients. European Journal of Haematology, 78, 389-398. https://doi.org/10.1111/j.1600-0609.2007.00834.x
Liu, X.H., Deng, C.X., Hu, P.C., Wang, Y. and Dong, Y.H. (2017) Functional Impact of Galectin-3 and TRAIL Expression in Breast Cancer Cells. European Review for Medical and Pharmacological Sciences, 21, 3626-3633.
Moriwaki, K., Shinzaki, S. and Miyoshi, E. (2011) GDP-Mannose-4,6-Dehydratase (GMDS) Deficiency Renders Colon Cancer Cells Resistant to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Receptor- and CD95-Mediated Apoptosis by Inhibiting Complex II Formation. The Journal of Biological Chemistry, 286, 3123-43133. https://doi.org/10.1074/jbc.M111.262741
Woo, J.K., Kang, J.H., Jang, Y.S., Ro, S., Cho, J.M., Kim, H.M., Lee, S.J. and Oh, S.H. (2015) Evaluation of Preventive and Therapeutic Activity of Novel Non-Steroidal Anti-Inflammatory Drug, CG100649, in Colon Cancer: Increased Expression of TNF-Related Apoptosis-Inducing Ligand Receptors Enhance the Apoptotic Response to Combination Treatment with TRAIL. Oncology Reports, 33, 1947-1955. https://doi.org/10.3892/or.2015.3793
Lemke, J., Noack, A., Adam, D., Tchikov, V., Bertsch, U., et al. (2010) TRAIL Signaling Is Mediated by DR4 in Pancreatic Tumor Cells Despite the Expression of Functional DR5. Journal of Molecular Medicine, 88, 729-740. https://doi.org/10.1007/s00109-010-0619-0
MacFarlane, M., Kohlhaas, S.L., Sutcliffe, M.J., Dyer, M.J. and Cohen, G.M. (2005) TRAIL Receptor-Selective Mutants Signal to Apoptosis via TRAIL-R1 in Primary Lymphoid Malignancies. Cancer Research, 65, 11265-11270. https://doi.org/10.1158/0008-5472.CAN-05-2801
Stadel, D., Mohr, A., Ref, C., MacFarlane, M., Zhou, S., et al. (2010) TRAIL-Induced Apoptosis Is Preferentially Mediated via TRAIL Receptor 1 in Pancreatic Carcinoma Cells and Profoundly Enhanced by XIAP Inhibitors. Clinical Cancer Research, 16, 5734-5749. https://doi.org/10.1158/1078-0432.CCR-10-0985
Van der Sloot, A.M., Tur, V., Szegezdi, E., Mullally, M.M., Cool, R.H., et al. (2006) Designed Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Variants Initiating Apoptosis Exclusively via the DR5 Receptor. Proceedings of the National Academy of Sciences of the United States of America, 103, 8634-8639. https://doi.org/10.1073/pnas.0510187103
Yu, R., Albarenque, S.M., Cool, R.H., Quax, W.J., Mohr, A., et al. (2014) DR4 Specific TRAIL Variants Are More Efficacious than Wild-Type TRAIL in Pancreatic Cancer. Cancer Biology & Therapy, 15, 1658-1666. https://doi.org/10.4161/15384047.2014.972183
Zhang, Y. and Zhang, B. (2008) TRAIL Resistance of Breast Cancer Cells Is Associated with Constitutive Endocytosis of Death Receptors 4 and 5. Molecular Cancer Research, 6, 1861-1871. https://doi.org/10.1158/1541-7786.MCR-08-0313
Shirley, S., Morizot, A. and Micheau, O. (2011) Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion. Recent Patents on Anti-Cancer Drug Discovery, 6, 311-323. https://doi.org/10.2174/157489211796957757
Yoldas, B., Ozer, C., Ozen, O., et al. (2011). Clinical Significance of TRAIL and TRAIL Receptors in Patients with Head and Neck Cancer. Head Neck, 33, 1278-1284. https://doi.org/10.1002/hed.21598
Koschny, R., Krupp, W., Xu, L.X., Mueller, W.C., Bauer, M., et al. (2015) WHO Grade Related Expression of TRAIL-Receptors and Apoptosis Regulators in Meningioma. Pathology—Research and Practice, 211, 109-116. https://doi.org/10.1016/j.prp.2014.11.002
Clancy, L., Mruk, K., Archer, K., Woelfel, M., Mongkolsapaya, J., et al. (2005) Preligand Assembly Domain-Mediated Ligand-Independent Association between TRAIL Receptor 4 (TR4) and TR2 Regulates TRAIL-Induced-Apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 102, 18099-18104. https://doi.org/10.1073/pnas.0507329102
Riccioni, R., Pasquini, L., Mariani, G., Saulle, E., Rossini, A., et al. (2005) TRAIL Decoy Receptors Mediate Resistance of Acute Myeloid Leukemia Cells to TRAIL. Haematologica, 90, 612-624.
Morizot, A., Merino, D., Lalaoui, N., Jacquemin, G., Granci, V., et al. (2011) Chemotherapy Overcomes TRAIL-R4-Mediated TRAIL Resistance at the DISC Level. Cell Death & Differentiation, 18, 700-711. https://doi.org/10.1038/cdd.2010.144
Verim, A., Turan, S., Farooqi, A.A., Kahraman, O.T., Tepe-Karaca, C., et al. (2014) Association between Laryngeal Squamous Cell Carcinoma and Polymorphisms in Tumor Necrosis Factor Related Apoptosis Induce Ligand (TRAIL), TRAIL Receptor and sTRAIL Levels. Asian Pacific Journal of Cancer Prevention, 15, 10697-10703. https://doi.org/10.7314/APJCP.2014.15.24.10697